Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 1/2011

01-02-2011 | Clinical Trial Report

OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine

Authors: Shih-Pin Chen, Jong-Ling Fuh, Shuu-Jiun Wang

Published in: Current Pain and Headache Reports | Issue 1/2011

Login to get access

Excerpt

Aurora SK, Dodick DW, Turkel CC, et al.: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30: 793–803. …
Literature
1.
Munakata J, Hazard E, Serrano D, et al.: Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009, 49:498–508.PubMedCrossRef
2.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):9–160.
3.
Dodick DW: Clinical practice. Chronic daily headache. N Engl J Med 2006, 354:158–165. (Published erratum appears in N Engl J Med 2006, 354:884.)PubMedCrossRef
4.
Aoki KR: Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 2002, 30:107–116.PubMedCrossRef
5.
Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM: Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669–676.PubMedCrossRef
6.
Schulte-Mattler WJ, Leinisch E: Evidence based medicine on the use of botulinum toxin for headache disorders. J Neural Transm 2008, 115:647–651.PubMedCrossRef
7.
Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315–324.PubMedCrossRef
8.
Silberstein S, Tfelt-Hansen P, Dodick DW, et al.: Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008, 28:484–495. (Published erratum appears in Cephalalgia 2008, 28:679.)PubMedCrossRef
9.
Blumenfeld AM, Schim JD, Chippendale TJ: Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008, 48:210–220.PubMedCrossRef
10.
Mathew NT, Jaffri SF: A double-blind comparison of onabotulinumtoxina (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009, 49:1466–1478.PubMedCrossRef
11.
Magalhães E, Menezes C, Cardeal M, Melo A: Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010, 112:463–466.PubMedCrossRef
12.
Diener HC, Schorn CF, Bingel U, Dodick DW: The importance of placebo in headache research. Cephalalgia 2008, 28:1003–1011.PubMedCrossRef
13.
Silberstein SD, Lipton RB, Dodick DW, et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170–180.PubMedCrossRef
14.
Diener HC, Bussone G, Van Oene JC, et al.: Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007, 27:814–823. (Published erratum appears in Cephalalgia 2007, 27:962.)PubMedCrossRef
15.
Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(Suppl 1):S9–S15.PubMedCrossRef
16.
Gazerani P, Pedersen NS, Staahl C, et al.: Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141:60–69.PubMedCrossRef
17.
Gazerani P, Au S, Dong X, et al.: Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010 Aug 20 (Epub ahead of print).
Metadata
Title
OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine
Authors
Shih-Pin Chen
Jong-Ling Fuh
Shuu-Jiun Wang
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 1/2011
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-010-0150-6

Other articles of this Issue 1/2011

Current Pain and Headache Reports 1/2011 Go to the issue

ReviewPaper

Updated Perspectives on Neurogenic Thoracic Outlet Syndrome

ReviewPaper

New Daily Persistent Headache: Controversy in the Diagnostic Criteria

ReviewPaper

Update on Hemicrania Continua

ReviewPaper

Managing the Placebo Effect: Enhancing the Signal-to-Noise Ratio

ReviewPaper

Treatment of Chronic Migraine

ReviewPaper

Chronic Migraine: Epidemiology and Disease Burden